title: Combining incretin-based drugs and RAAS inhibitors: more cons than pros?
authors.affiliation: Diabetes Centre, Department of Internal Medicine, VU University Medical Centre, 1081 HV, Amsterdam, Netherlands. Electronic address: l.tonneijck@vumc.nl.
authors.forename: Lennart
authors.initials: L
authors.lastname: Tonneijck
authors.affiliation: Diabetes Centre, Department of Internal Medicine, VU University Medical Centre, 1081 HV, Amsterdam, Netherlands.
authors.forename: Marcel H A
authors.initials: MH
authors.lastname: Muskiet
authors.affiliation: Diabetes Centre, Department of Internal Medicine, VU University Medical Centre, 1081 HV, Amsterdam, Netherlands.
authors.forename: Mark M
authors.initials: MM
authors.lastname: Smits
authors.affiliation: Diabetes Centre, Department of Internal Medicine, VU University Medical Centre, 1081 HV, Amsterdam, Netherlands.
authors.forename: Daniël H
authors.initials: DH
authors.lastname: van Raalte
authors.affiliation: Diabetes Centre, Department of Internal Medicine, VU University Medical Centre, 1081 HV, Amsterdam, Netherlands.
authors.forename: Michaela
authors.initials: M
authors.lastname: Diamant
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D054795:Incretins / Q000008:administration & dosage*; D018570:Risk Assessment; D016896:Treatment Outcome; D000092502:Renin Inhibitors
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D054795:Incretins; D000092502:Renin Inhibitors